A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Authors

Lincoln W. Pasquina (ORCID: https://orcid.org/0009-0009-5461-9777)
Edmund Folefac (ORCID: https://orcid.org/0000-0001-5510-7073)
Rahul R. Parikh (ORCID: https://orcid.org/0000-0002-7152-750X)
Mamta Parikh (ORCID: https://orcid.org/0000-0002-7300-7452)
Adam C. Olson (ORCID: https://orcid.org/0000-0002-0771-9486)
Christina Jamieson (ORCID: https://orcid.org/0000-0001-5328-2628)
Archana Ajmera (ORCID: https://orcid.org/0000-0002-4509-0447)
Eliezer M. Van Allen (ORCID: https://orcid.org/0000-0002-0201-4444)
Geoffrey Ira Shapiro (ORCID: https://orcid.org/0000-0002-3331-4095)
Sarah Clifford (ORCID: https://orcid.org/0000-0002-5799-7214)
Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
Christos E. Kyriakopoulos (ORCID: https://orcid.org/0000-0002-6452-7405)
Biren Saraiya (ORCID: https://orcid.org/0000-0002-3522-4579)
Wanling Xie (ORCID: https://orcid.org/0000-0001-5995-8000)
Merrida Childress (ORCID: https://orcid.org/0000-0002-0854-784X)
Arlene Araneta (ORCID: https://orcid.org/0000-0002-6735-2727)
Amaya Gascó Hernández (ORCID: https://orcid.org/0000-0002-2838-9076)
S. Percy Ivy (ORCID: https://orcid.org/0000-0001-7747-072X)
Bose Kochupurakkal (ORCID: https://orcid.org/0000-0001-8929-3070)
Arif Hussain (ORCID: https://orcid.org/0000-0001-8485-4406)

Institutions

Rutgers, The State University of New Jersey (US)
University of Maryland, Baltimore (US)
National Institutes of Health (US)
University of Maryland Medical Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
University of California San Diego (US)
University of Wisconsin Carbone Cancer Center (US)
Dana-Farber Cancer Institute (US)
UPMC Hillman Cancer Center (US)
National Cancer Institute (US)
Rutgers Cancer Institute (US)
UC Davis Comprehensive Cancer Center
Foundation Medicine (United States)
The Ohio State University (US)
University of California, Davis (US)

Publication Details

Journal: Journal of Clinical Oncology
Published: 2025-05-28
DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5007
Citations: 5
Primary Topic: Prostate Cancer Treatment and Research
Type: article
Field-Weighted Citation Impact: 7.59

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Lincoln W. Pasquina, Edmund Folefac, Rahul R. Parikh, Mamta Parikh, Adam C. Olson, Christina Jamieson, Archana Ajmera, Eliezer M. Van Allen, Geoffrey Ira Shapiro, Sarah Clifford, Rana R. McKay, Christos E. Kyriakopoulos, Biren Saraiya, Wanling Xie, Merrida Childress, Arlene Araneta, Amaya Gascó Hernández, S. Percy Ivy, Bose Kochupurakkal, Arif Hussain

May 28, 2025article en

5 citations

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Authors

Institutions

Publication Details

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.